Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways

American Journal of Physiology - Cell Physiology

Volumn 302, Issue 4, 2012, Pages

  Cersosimo, Eugenio ^a   Xu, Xiaojing ^a   Musi, Nicolas ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cell proliferation; Hyperinsulinemia; Vascular dysfunction

Indexed keywords

INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PALMITIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE;

ARTICLE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; DOSE RESPONSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INFLAMMATION; INSULIN SENSITIVITY; METABOLISM; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

CELL COMMUNICATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84863052099     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00022.2011     Document Type: Article

References (36)

1. American Heart Association. Heart Disease and Stroke Statistics-Update. Dallas, TX: American Heart Association, 2003.
2. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, DeFronzo RA, Cusi K. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54: 1640-1648, 2005.
3. Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: new implications. Vascul Pharmacol 4: 3-18, 2006.
4. Cersosimo E, DeFronzo RA. Insulin resistance, and endothelial dysfunction: the road map for cardiovascular diseases. Diabetes Metab Res Rev 22: 423-436, 2006.
5. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn RC, Mandarino L. Insulin resistant differentially affects PI-3 kinase and MAP-kinase-mediated signaling in human muscle. J Clin Invest 105: 311-320, 2000.
6. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino Sr R, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction ofcarotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117: 2123-2130, 2008.
7. Draznin B. Mitogenic action of insulin: friend, foe or "frenemy"? Diabetologia 53: 229-233, 2010.
8. Esfandiarei M, Larn JT, Yazdi SA, Kariminia A, Dorado JN, Kuzeljevic B, Syyong HT, Hu K, van Breemen C. Diosgenin modulates vascular smooth muscle cell function by regulating cell viability, migration and calcium homeostasis. J Pharmacol Exp Ther 336: 925-939, 2011.
9. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes 58: 2238-2245, 2009.
10. Goya K, Sumitani S, Sotsuki M, Xu X, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S. The thiaozolidenidione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications 20: 336-342, 2006.
11. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity: reversal with intra-myocellular fat depletion. Diabetes 51: 144-151, 2002.
12. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
13. Hsueh WA. Insulin signals in the arterial wall. J Cardiology 84: 215-245, 1999.
14. Hsueh WA, Law RE. PPAR atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
15. Isomaa B, Almgren P, Tuomi T, Forsen B, Lathi K, Nissen M, Taskinen M, Groop L. Cardiovascular morbidity, and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
16. Kannel WB, Framingham Heart Study Group. Relative risk of CVD in subjects with and without diabetes: Framingham Heart Study. Am Heart J 120: 672-676, 1990.
17. Kelley DE, Mokan M, Mandarino L. Intracellular defects in glucose metabolism in obese patients with non-insulin dependent diabetes mellitus. Diabetes 41: 698-706, 1992.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta-Delta C(T)] Method. Methods 25: 402-408, 2001.
19. Ludmer P, Selwyn A, Shook T, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051, 1986.
20. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296: 2572-2581, 2006.
21. Musi N, Fuji N, Hirshman MF, Ekberg I, Froberg S, Ljungqvist O, Thorell A, Goodyear LJ. AMP-activated protein kinase (AMP-kinase) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50: 921-927, 2001.
22. Nissen SE, Nichols SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, Larchelliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes (The Periscope Randomized Controlled Trial). JAMA 299: 1561-1573, 2008.
23. Pan H, Chen J, Xu J, Ma R. Anti-fibrotic effect by activation of peroxisome proliferator-activated receptor gamma in corneal fibroblasts. Mol Vis 15: 2279-2286, 2009.
24. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106: 165-169, 2000.
25. Gaede, P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591, 2008.
26. Ralph DeFronzo A. Claude Bernard Lecture, European Association for the Study of Diabetes Annual Meeting, Rome, Italy, 2008.
27. Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, DeFronzo RA, Coletta RK, Sriwijitkamol A, Musi N. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 57: 2595-2602, 2008.
28. Ross R. Pathogenesis of atherosclerosis. N Engl J Med 340: 115-126, 1999.
29. Rothman D, Shulman R, Shulman G. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphatase: evidence for reduced insulin-dependent muscle glucose transport of phosphorylation in noninsulin dependent diabetes mellitus. J Clin Invest 89: 1069-1075, 1992.
30. Shulman GI. Cellular mechanism of insulin resistance. J Clin Invest 106: 171-176, 2000.
31. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 97: 2601-2610, 1996.
32. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR. Coronary artery disease risk factors in Type 2 Ddiabetes based on time to first event: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828, 1998.
33. Tong NW, Wang Q, Liu XJ, Wu X. In vitro study to the effects of pioglitazone on endothelial cell functions of human umbilical vein and the mechanism involved. Jul 36: 525-528, 2005 (Original in Chinese).
34. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 45: 19-28, 2006.
35. Wajcberg E, Thappil N, Fernandez M, Patel S, Hale D, DeFronzo RA, Cersosimo E. Comprehensive assessment of vascular reactivity in Hispanic children and adults with and without diabetes mellitus. Pediatric Diabetes 7: 329-335, 2006.
36. Wajcberg E, Fernandez M, DeFronzo RA, Cersosimo E. Relationship between improvements in metabolic control, lipids, and vascular reactivity in Mexican-American with Type 2 diabetes mellitus treated with Pioglitazone. J Clin Endo Metabol 92: 1256-1262, 2007.